Tibet Duo Rui Pharmaceutical Co

Tibet Duo Rui Pharmaceutical Co Equity

The The Equity of Tibet Duo Rui Pharmaceutical Co (301075.SZ) as of Oct 23, 2026 is 574.51 M CNY. In the previous year, The Equity was 676.73 M CNY — a change of -15.10% (lower).

Equity

574.51 MCNY

YoY

-15.10%

Last updated:

In 2025, Tibet Duo Rui Pharmaceutical Co's equity was 574.51 M CNY, a -15.10% increase from the 676.73 M CNY equity in the previous year.

The Tibet Duo Rui Pharmaceutical Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
74.22 M CNY
Jan 1, 2019
150.37 M CNY
Jan 1, 2020
242.36 M CNY
Jan 1, 2021
792.92 M CNY
Jan 1, 2022
751.53 M CNY
Jan 1, 2023
772.06 M CNY
Jan 1, 2024
676.73 M CNY
Jan 1, 2025
574.51 M CNY
The Tibet Duo Rui Pharmaceutical Co Equity history
YEAREquityYoY
574.51 MCNY-15.10%
676.73 MCNY-12.35%
772.06 MCNY+2.73%
751.53 MCNY-5.22%
792.92 MCNY+227.16%
242.36 MCNY+61.17%
150.37 MCNY+102.61%
74.22 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Duo Rui Pharmaceutical Co Stock analysis

What does Tibet Duo Rui Pharmaceutical Co do? Tibet Duo Rui Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical preparations and their raw materials. The company's core product, sodium acetate ringer injection, is used for supplementing body fluids, regulating electrolyte balance, and correcting acidosis. Additional products include compound electrolyte injection, compound mannitol injection, and cefotaxime sodium for injection, which are sold to healthcare providers and hospitals. The firm targets the pharmaceutical market segment focused on fluid and electrolyte management and antibiotic treatments. The company's revenue streams are derived from the sale of its proprietary chemical preparations, with sodium acetate ringer injection representing a key product line. Compound electrolyte injection and compound mannitol injection cater to specific medical needs, while cefotaxime sodium for injection serves as an antibiotic solution. These products are distributed to hospitals and healthcare facilities within China's pharmaceutical distribution network. Tibet Duo Rui Pharmaceutical's business model centers on developing and commercializing specialized injectable solutions for clinical use. The firm's product portfolio addresses critical healthcare requirements, including fluid replacement, electrolyte regulation, and infection treatment. Sales are directed toward medical institutions that require these specialized pharmaceutical products for patient care. Tibet Duo Rui Pharmaceutical Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Tibet Duo Rui Pharmaceutical Co's Equity

Tibet Duo Rui Pharmaceutical Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Tibet Duo Rui Pharmaceutical Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Tibet Duo Rui Pharmaceutical Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Tibet Duo Rui Pharmaceutical Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Tibet Duo Rui Pharmaceutical Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Tibet Duo Rui Pharmaceutical Co stock

The Equity of Tibet Duo Rui Pharmaceutical Co is 574.51 M CNY in 2025.

The Equity of Tibet Duo Rui Pharmaceutical Co changed from 676.73 M CNY to 574.51 M CNY, representing a -15.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Tibet Duo Rui Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Tibet Duo Rui Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Tibet Duo Rui Pharmaceutical Co

All Key Metrics — Tibet Duo Rui Pharmaceutical Co